
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc. is recognized for its innovative approach to developing therapies for orphan pulmonary and fibrosis indications, boasting two Phase 2-ready clinical assets with promising trial results. Notable findings from the LTI-03 trial reveal increased sRAGE levels in recipients, indicating positive pharmacodynamic activity and bolstering the potential efficacy of its product candidates. The company's robust pipeline and the opportunity to address significant market needs in areas lacking effective treatments present a favorable risk-reward profile that positions Rein Therapeutics for potential outperformance in the coming year.
Bears say
Rein Therapeutics Inc. has experienced a significant decline in its stock value, reflecting a 50% drop year to date in 2025, which starkly contrasts with the 3.5% increase in the XBI index. This downturn has been largely attributed to the company’s decision to pause clinical trial enrollments in the U.S., leading to heightened uncertainty among investors regarding the future of its product candidates. Additionally, concerning data related to lower sRAGE levels, which have been correlated with poor survival rates in patients with Idiopathic Pulmonary Fibrosis, may further dampen confidence in the company's therapeutic prospects and overall viability.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares